Download PDF
Hamostaseologie 1988; 08(03): 129-135
DOI: 10.1055/s-0038-1659874
Originalarbeiten
Schattauer GmbH

Hormonale Kontrazeption und Blutgerinnung

R. von Hugo
1   Frauenklinik und Poliklinik der Technischen Universität München im Klinikum rechts der Isar, München
,
Husmann Ulrike
1   Frauenklinik und Poliklinik der Technischen Universität München im Klinikum rechts der Isar, München
,
R. Hafter
1   Frauenklinik und Poliklinik der Technischen Universität München im Klinikum rechts der Isar, München
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Asted B. Oral contraception and some debatable side effects. Acta Obstet Gynaecol Scand Suppl 1982; 105: 17-23.
    PubMedGoogle Scholar
  • 2 Baele G, Kaufman J.M, Thiery M, Vermeu-len A, Barbier F. Plasminogen, fibrinogen, α2-antiplasmin and antithrombin III levels during a single cycle of a combined oral contraceptive regime. Acta Clin Belg 1981; 36: 280-5.
    CrossrefPubMedGoogle Scholar
  • 3 Barnes R.W, Krapf T, Hoak J.C. Eroneous clinical diagnosis of leg vein thrombosis in women on oral contraceptives. Obstet Gynecol 1978; 51: 556-8.
    CrossrefPubMedGoogle Scholar
  • 4 Beller F, Ebert C.h. Effects of oral contraceptives on blood coagulation. A review Obstet Gynecol Surv 1985; 40: 425-36.
    PubMedGoogle Scholar
  • 5 Holt H.M. (Hrsg) Gestagene in oralen Kontrazeptiva. Berlin: Springer; 1984
    Google Scholar
  • 6 Böttiger L.E, Westerholm B. Oral contraceptives and thromboembolic disease -Swedish experience. Acta Med Scand 1971; 190: 455-63.
    PubMedGoogle Scholar
  • 7 Branson H.E, Katz J, Marble R, Griffin J.H. Inherited protein C deficiency and cou-marin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983; 2: 1165-8.
    PubMedGoogle Scholar
  • 8 Conard J, Cazenave B, Samama M, Horel-lou M.H, Zorn J.R, Neau C. AT III content and antithrombin activity in oestrogen-pro-geston and progeston-only treated women. Thromb Res 1980; 18: 675-81.
    CrossrefPubMedGoogle Scholar
  • 9 Engel H.J, Engel E, Lichtlen P. Coronary atherosclerosis and myocardial infarction in young women – role of oral contraceptives. Eur Heart J 1983; 4: 1-6.
    PubMedGoogle Scholar
  • 10 Graeff H. Hypocoagulable states. In: The Thromboembolic Disorders. Van de Loo J. et al. (Hrsg) Stuttgart; Schattauer: 1983: 91-105.
    Google Scholar
  • 11 Graeff H, Battis P, Hafter R, Zander J. Evaluation of hypercoagulability in users of oral contraceptives. Klin Wschr 1977; 55: 175-9.
    CrossrefPubMedGoogle Scholar
  • 12 Griffin J.H. Clinical studies of protein C. Semin Thromb Hemost 1984; 10: 162-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Hugo R von. Thromboserisiko – vor Operation Pille absetzen?. Medical Tribune 1987; 21: 27.
    PubMedGoogle Scholar
  • 14 Hugo R von. Wann ist Antithrombin-III-Bestimmung bei Verordnung der »Pille« indiziert?. Gynäkol prax 1986; 10: 83-5.
    PubMedGoogle Scholar
  • 15 Hugo R von, Kaiser P.M, Loos W. Die Bedeutung von Sexualsteroiden für die Entstehung von venösen Gefäßerkrankungen bei der Frau. In: Hormonale Kontrazeption und Kreislauf. Beller F.K. et al. (Hrsg) Gräfelfing: socio-medico; 1986. S 112-9.
    Google Scholar
  • 16 Jordan W.M. Pulmonary embolism. Lancet 1961; II: 1146-7.
    PubMedGoogle Scholar
  • 17 Kruskal J.B, Commerford P.J, Franks J.J, Kirsh R.E. Fibrin and fibrinogenrelated antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 22: 1361-5.
    PubMedGoogle Scholar
  • 18 Larsen E.H, Hauge E.N. Cardiovascular mortality trends in Denmark before and after introduction of oral contraceptives. Ugeskr Laeger 1984; 146: 2677-80.
    PubMedGoogle Scholar
  • 19 Layde P.M, Beral V. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners’ Oral Contraception Study. Lancet 1981; I: 541-6.
    PubMedGoogle Scholar
  • 20 Mammen E. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781-90.
    CrossrefPubMedGoogle Scholar
  • 21 Meade T, Stirling Y, Wilkes H, Manucci P. Effects of oral contraceptives and obesity on protein C antigen. Thromb Haemostas 1985; 53: 198-9.
    PubMedGoogle Scholar
  • 22 Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-6.
    CrossrefPubMedGoogle Scholar
  • 23 Notelovitz M. Oral contraception and coagulation. Clin Obstet Gynecol 1985; 28: 73-83.
    CrossrefPubMedGoogle Scholar
  • 24 Owen W.G. Protein C. In: Hemostasis and Thrombosis. Coleman R.W. et al. (eds) Philadelphia; Lippincott: 1987: 235-42.
    Google Scholar
  • 25 Rabe T, Runnebaum B. (Hrsg) Kontrazeption. Berlin: Springer; 1982
    Google Scholar
  • 26 Rosenberg L, Kaufmann D.W, Helmrich S.P, Miller D.R, Stolley P.D, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. J Amer Med Assoc 1985; 20: 2965-9.
    PubMedGoogle Scholar
  • 27 Royal College of General Practitioners’ Oral Contraception Study. Incidence of arterial disease among oral contraceptive users. J R Coll Gen Pract 1983; 33: 75-82.
    PubMedGoogle Scholar
  • 28 Royal College of General Practitioners’ Oral Contraception Study. Oral contraceptives, venous thrombosis and varicous venes. J R Coll Gen Pract 1978; 28: 393-9.
    PubMedGoogle Scholar
  • 29 Runnebaum B, Rabe T. (Hrsg) Hormonale Kontrazeption. Darmstadt: Steinkopff; 1985
    Google Scholar
  • 30 Sagar S, Stamatakis J.D, Thomas D.P, Kakkar V. Oral contraceptives, antithrom-bin-III activity, and postoperative deep vein thrombosis. Lancet 1976; 1: 509-11.
    PubMedGoogle Scholar
  • 31 Sinzinger H. Thrombose, Hämostase und Prostazyklin. Inn Med 1983; 10: 71-8.
    PubMedGoogle Scholar
  • 32 Stadel B.V. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-8 672-7.
    CrossrefPubMedGoogle Scholar
  • 33 Ulstein M, Svendsen E, Steier A, Bratt H, Fylling P, Lie S, Schifloe A. Aaserud Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand 1984; 63: 233-6.
    CrossrefPubMedGoogle Scholar
  • 34 Vessey M.P. Female hormons and vascular disease – an epidemiological overview. Br J Fam Plan Suppl 1980; 6: 1-12.
    PubMedGoogle Scholar
  • 35 Weenink G.H, ten Cate J.W, Carle L.H, Lamping R.J, Treffers P.E. »Morning-after pill« and antithrombin-III. Acta Obstet Gynaecol Scand 1983; 62: 359-63.
    PubMedGoogle Scholar
  • 36 Wisemann R.A, MacRae K.G. Oral contraceptives and the decline in mortality from circulatory disease. Fértil Steril 1981; 35: 277-83.
    PubMedGoogle Scholar
  • 37 Ylikokala O, Poulakka J, Viinikka L. The effect of oral contraceptives on antiaggregatory prostacyclin and proaggregatory thromboxane A2 in humans. Am J Obstet Gynecol 1982; 142: 573-5.
    CrossrefPubMedGoogle Scholar